BioSpace News Archive

Plan to study bamlanivimab in a diverse group of participants, including Native American communities

Endo International plc announced that members of management will present at the J.P. Morgan Healthcare Conference on Tuesday, January 12, 2021 at 2:50 p.m. EST.

Castle Biosciences, Inc., announced the closing of its previously announced underwritten public offering of 4,600,000 shares of its common stock, including the exercise in full by the underwriters of their option to purchase an additional 600,000 shares, at a public offering price of $58.00 per share.

Action Follows Thorough Evaluation of Available Safety, Effectiveness, and Manufacturing Quality Information by FDA Career Scientists, Input from Independent Experts

Health Canada is aware that the U.S. Food and Drug Administration has issued an emergency use authorization for a COVID-19 vaccine manufactured by Moderna.

Qu Biologics Inc., a private clinical stage biopharmaceutical company developing Site Specific Immunomodulators (SSIs), a novel platform of immunotherapies designed to restore innate immune function, is pleased to announce it is receiving advisory services and research and development funding from the National Research Council of Canada Industrial Research Assistance Program (NRC IRAP) to quickly move forward the potential applic

Therap offers Person-Centered Planning Tools to accommodate the essential problem-solving process which can be used to assist individuals in Long-Term Services and Supports (LTSS) settings

Horizon Healthcare Services, Inc. (Horizon), New Jersey’s largest health plan, and Geneia , a healthcare analytic solutions and services company that is simplifying the transition to value-based care, announce their partnership to advance population health is working. Horizon chose Geneia’s Theon ® Platform for Population Anal

Scientists have created a three-dimensional map of a complex of molecules that plays a fundamental role in life – and which when it goes wrong is linked to increased sensitivity to viral infections and neurodegenerative diseases.

The U.S. Food and Drug Administration approved the Osseoanchored Prostheses for the Rehabilitation of Amputees Implant System, the first implant system marketed in the U.S. for adults who have transfemoral—or above-the-knee—amputations and who have or are anticipated to have rehabilitation problems with, or cannot use, a conventional socket prosthesis.